

Title (en)

COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND BODY WEIGHT RELATED DISORDERS

Title (de)

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN UND GEWICHTSPROBLEMEN

Title (fr)

COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DE TROUBLES MÉTABOLIQUES ET TROUBLES ASSOCIÉS AU POIDS CORPOREL

Publication

**EP 3039022 A4 20170816 (EN)**

Application

**EP 14841043 A 20140829**

Priority

- US 201314013918 A 20130829
- US 201314052074 A 20131011
- US 201414270130 A 20140505
- US 2014053334 W 20140829

Abstract (en)

[origin: WO2015031710A1] The present invention relates to compounds, pharmaceutical compositions and formulations that have a tripartite structure A-B-C having having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently. Also provided are methods for treating a metabolic disorder or a cell hyperproliferative disease with the compounds, pharmaceutical compositions and formulations described herein. Further provided are methods for reducing body weight or increasing thermogenesis during weight loss with the compounds of structure A-B-C, as described, or of structure Formula where R1 is H, Et, OMe or n-propyl; Y is CH or (formula); R2 is OH, OMe, or NH-i-Pr; R3 is H, F, or Cl; and R4 is H, Me, Cl, Br, F, OH, OBz, OCH2COOMe, OCH2COOH, NH2, NH-i-Pr, NHCOMe, NHSO2Me, NHBn (formula), OMe, NHBoc, (formula), NHTs, (formula), or (formula); or pharmaceutically acceptable salt or stereoisomer thereof or both.

IPC 8 full level

**C07D 417/04** (2006.01); **A61K 31/426** (2006.01); **A61K 31/4439** (2006.01); **A61P 3/00** (2006.01); **C07D 213/06** (2006.01); **C07D 231/06** (2006.01); **C07D 277/22** (2006.01); **C07D 277/24** (2006.01); **C07D 277/66** (2006.01); **C07D 417/14** (2006.01)

CPC (source: EP)

**A61K 31/426** (2013.01); **A61K 31/428** (2013.01); **A61K 31/4439** (2013.01); **A61P 1/16** (2017.12); **A61P 3/00** (2017.12); **A61P 3/04** (2017.12); **A61P 3/06** (2017.12); **A61P 3/10** (2017.12); **A61P 9/10** (2017.12); **A61P 9/12** (2017.12); **A61P 11/06** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 35/04** (2017.12); **A61P 43/00** (2017.12); **C07D 213/06** (2013.01); **C07D 213/76** (2013.01); **C07D 231/06** (2013.01); **C07D 235/14** (2013.01); **C07D 277/22** (2013.01); **C07D 277/24** (2013.01); **C07D 277/52** (2013.01); **C07D 277/66** (2013.01); **C07D 295/192** (2013.01); **C07D 417/04** (2013.01); **C07D 417/12** (2013.01); **C07D 417/14** (2013.01); **C07D 471/04** (2013.01); **C07D 487/04** (2013.01)

Citation (search report)

- [X] WO 2008097835 A2 20080814 - BAYLOR COLLEGE MEDICINE [US], et al
- [X] WO 2013110007 A1 20130725 - UNIV COLUMBIA [US], et al
- [X] WO 2005044194 A2 20050519 - PHARMACIA CORP [US], et al
- [X] WO 2004103959 A2 20041202 - AMBIT BIOSCIENCES CORP [US], et al
- See references of WO 2015031710A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

**WO 2015031710 A1 20150305**; AU 2014312227 A1 20160421; CA 2922703 A1 20150305; CN 107074839 A 20170818; EP 3039022 A1 20160706; EP 3039022 A4 20170816; JP 2016534124 A 20161104

DOCDB simple family (application)

**US 2014053334 W 20140829**; AU 2014312227 A 20140829; CA 2922703 A 20140829; CN 201480058587 A 20140829; EP 14841043 A 20140829; JP 2016537878 A 20140829